These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24300419)

  • 1. Dendritic cell c-kit signaling and adaptive immunity: implications for the upper airways.
    Oriss TB; Krishnamoorthy N; Ray P; Ray A
    Curr Opin Allergy Clin Immunol; 2014 Feb; 14(1):7-12. PubMed ID: 24300419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling of c-kit in dendritic cells influences adaptive immunity.
    Ray P; Krishnamoorthy N; Oriss TB; Ray A
    Ann N Y Acad Sci; 2010 Jan; 1183():104-22. PubMed ID: 20146711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging functions of c-kit and its ligand stem cell factor in dendritic cells: regulators of T cell differentiation.
    Ray P; Krishnamoorthy N; Ray A
    Cell Cycle; 2008 Sep; 7(18):2826-32. PubMed ID: 18787413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.
    Smrž D; Bandara G; Zhang S; Mock BA; Beaven MA; Metcalfe DD; Gilfillan AM
    J Immunol Methods; 2013 Apr; 390(1-2):52-62. PubMed ID: 23357051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RIN3 is a negative regulator of mast cell responses to SCF.
    Janson C; Kasahara N; Prendergast GC; Colicelli J
    PLoS One; 2012; 7(11):e49615. PubMed ID: 23185384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases.
    Reber L; Da Silva CA; Frossard N
    Eur J Pharmacol; 2006 Mar; 533(1-3):327-40. PubMed ID: 16483568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
    Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
    Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
    Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
    Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
    Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
    Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop.
    Levina V; Marrangoni A; Wang T; Parikh S; Su Y; Herberman R; Lokshin A; Gorelik E
    Cancer Res; 2010 Jan; 70(1):338-46. PubMed ID: 20028869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cell-dendritic cell crosstalk in the initiation of immune responses.
    Walzer T; Dalod M; Vivier E; Zitvogel L
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S49-59. PubMed ID: 16187940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells.
    Litz J; Krystal GW
    Mol Cancer Ther; 2006 Jun; 5(6):1415-22. PubMed ID: 16818499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
    Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
    Mol Cancer; 2006 Oct; 5():46. PubMed ID: 17044945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role for c-kit (CD117) in T cell lineage commitment and early thymocyte development in vitro.
    Massa S; Balciunaite G; Ceredig R; Rolink AG
    Eur J Immunol; 2006 Mar; 36(3):526-32. PubMed ID: 16482516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development.
    Agosti V; Corbacioglu S; Ehlers I; Waskow C; Sommer G; Berrozpe G; Kissel H; Tucker CM; Manova K; Moore MA; Rodewald HR; Besmer P
    J Exp Med; 2004 Mar; 199(6):867-78. PubMed ID: 15024050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
    Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
    Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
    Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
    Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niche anchorage and signaling through membrane-bound Kit-ligand/c-kit receptor are kinase independent and imatinib insensitive.
    Tabone-Eglinger S; Calderin-Sollet Z; Pinon P; Aebischer N; Wehrle-Haller M; Jacquier MC; Boettiger D; Wehrle-Haller B
    FASEB J; 2014 Oct; 28(10):4441-56. PubMed ID: 25002122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
    Merchant MS; Woo CW; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.